Pfizer, BioNTech Gain On Signing Deal With EU For 1.8 Billion More Doses By

<iframe src=”//″ width=”250″ height=”250″ scrolling=”no” border=”0″ marginwidth=”0″ style=”border:none;” frameborder=”0″></iframe>

© Reuters

By Dhirendra Tripathi – Pfizer (NYSE:) and BioNTech SE (NASDAQ:), joint developers of a Covid-19 vaccine, were both up Thursday after the two reached an agreement with the European Union to supply up to 1.8 billion more doses of the shot.

The first supply will comprise 900 million shots with an option for the bloc to request as many doses again.

This new agreement is in addition to the 600 million doses that have already been committed to the EU through 2021.

The first lot is expected to be delivered monthly beginning December 2021 and continuing into 2023.

The total number of potential doses delivered to the EU, inclusive of all agreements, now stands at 2.4 billion.

The vaccine is based on BioNTech’s proprietary mRNA technology. The two companies have geographies demarcated to distribute the shots.  



Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.


85 − = 78